Covid19, Virus-HIV
Conditions
Brief summary
The non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into teleconsultation or exchanges of e-mails between practitioners and patients during COVID-19 epidemic. This change in care can have an impact on follow-up and access to treatment for PVVIH.
Detailed description
On 16 March 2020, an instruction to postpone non-urgent consultations was given to doctors. Thus, the non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into teleconsultation or exchanges of e-mails between practitioners and patients. This change in care can have an impact on follow-up and access to treatment for PVVIH. In addition, the epidemic itself may have consequences: PVVIH may be at greater risk because of their immunosuppression and associated co-morbidities.
Interventions
OTHERquestionnaire
bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
Sponsors
Tourcoing Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient followed up for HIV infection in one of the COREVIH Hauts de France centres participating in the study * Having communicated an email address * Having given their consent to participate in this study * Beneficiary subject affiliated or entitled to a social security scheme
Exclusion criteria
* Minor patient * Refusal to participate * Patient under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of SARS CoV2 infection in PVVIH in Hauts de France | Inclusion | Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at inclusion in the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of SARS CoV2 infection in PVVIH in Hauts de France | through study completion, an average of 19 months | Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at the end of the study |
| Determine the incidence rate of COVID 19 among PVVIH discontinuing antiretroviral treatment | through study completion, an average of 19 months | Reason for discontinuing antiretroviral treatment |
| Determine the incidence rate of COVID 19 among PVVIH antiretroviral treatment | through study completion, an average of 19 months | Percentage of patients who stopped their antiretroviral treatment |
| Psychological consequences of this epidemic among PVVIH : HAD | through study completion, an average of 19 months | Evaluation of the psychological scales HAD on PVVIH |
| Psychological consequences of this epidemic among PVVIH : PROQOL-HIV | through study completion, an average of 19 months | Evaluation of the psychological scales PROQOL-HIV on PVVIH |
| Determine the incidence rate of COVID 19 among PVVIH who stopped all follow-up | through study completion, an average of 19 months | Percentage of patients who stopped all follow-up by an infectious disease specialist |
Countries
France
Outcome results
None listed